Next generation of
heart disease diagnosis

Ensuring that patients worldwide have
access to heart disease diagnosis
and treatment.

Cardio Intelligence Inc.

Philosophy

We support medical practices facing a shortage of cardiologists
by providing AI-based medical device software and cloud services.
Our aim is to build a brighter future by improving access to ECG tests
for arrhythmia patients and assisting them.

MISSION

Providing every patient with the opportunity to receive diagnosis and treatment for heart disease.

VISION

Supporting medical professionals worldwide with technology.

VALUE

Development of medical devices that are truly beneficial in the medical field.

CEO Message

Shigemasa Sasaki
CEOShigemasa Sasaki

Any ECG device, one AI, timely answers for every physician

Heart disease remains the world's leading cause of death, yet the ECG, the most widely used cardiac test, has barely evolved in decades. Reading it still depends on scarce specialists, and about half of paroxysmal atrial fibrillation (AF) cases are missed by conventional 24-hour monitoring.

SmartRobin, our patented deep-learning AI for AF, changes this. Its greatest strength is that it works with any ECG device. Data from any Holter, patch or wearable, single-lead or multi-lead, is converted into a standard format and analyzed by the same engine, so hospitals and clinics anywhere can adopt it without changing their existing equipment.

Speed matters just as much. A full 7-day ECG is analyzed in about 30 minutes with 95% accuracy, and 80% of reports reach physicians within one day, giving them timely feedback when treatment decisions matter most.

Approved in Japan and covered by insurance, SmartRobin has passed >30,000 total orders, with up 56% year on year. We are now extending it to detect hidden AF from just five minutes of ECG and to predict AF risk within seven days.

Our goal is to make early detection of heart disease a global standard, creating lasting value for patients, clinicians and partners alike.

Products

SmartRobin AI Series is a long-term ECG analysis software that automatically detects atrial fibrillation (AF). AF is a major cause of stroke and can be prevented through early diagnosis and treatment.

However, detection of AF is difficult for non-specialists in the field of cardiology, and furthermore, ECG analysis is time-consuming and labor-intensive.

The quick ECG analysis by the SmartRobin AI Series will not only solve problems experienced by medical professionals, but will also contribute to reducing the burden of hospital visits for patients.

*This product is only available in Japan at this time.

Portfolio

In addition to the existing SmartRobin projects, following three pipelines are in progress.

portfolio

Company History

2019
June: Acquired Type II Marketing License for Medical Devices. Acquired Medical Device Manufacturer registration.
October: Head office was founded at 35-1, Higashiazabu 2-chome, Minato-ku, Tokyo.
2020
August: Raised 35 million JPY in seed round funding
August: Adopted by the Japan Agency for Medical Research and Development (AMED) as a Research Project for the Promotion of Medical Device Development.
October: Our initiatives introduced to four Asian countries as Japan Healthcare Services as part of the Asian Health Initiative promoted by the Cabinet Secretariat.
2021
February: Raised 140 million JPY in Pre-Series A funding
June: Adopted by the PwC Foundation as a grant recipient for 2021.
September: Started joint development with JSR Corporation, a manufacturer of long-term ECG.
October: Adopted for the Tokyo Metropolitan Government's 13th Subsidy Program to Support the Commercialization of Medical Devices
December: Obtained the First Product (Software as a Medical Device) certification
2022
January: Obtained patent No. 7002168.
April: Launched The long-term ECG analysis software, SmartRobin AI Series
April: Received the "Medtec Grand Prize" at the 10th Medtec Innovation Awards
May: Head office relocated to 1-25-5, Higashiazabu, Minato-ku, Tokyo
June: Obtained license to sell and lend highly controlled medical device
August: Raised 430 million JPY in Series A funding
October: Adopted for the Tokyo Metropolitan Government's Advanced Medical Device Acceleration Project
November: Signed a business alliance agreement with the International University of Health and Welfare for industry- academia collaboration
November: Raised an additional 200 million JPY in Series A funding
2023
May: Obtained the ISO 27001 certification, the international ISMS standard.
2024
March: Raised an additional funds
2025
Series B funding raised

Investors

Company Information

Company Name Cardio Intelligence Inc.
Location Head office: VORT Azabu East 2F, 1-25-5 Higashi-Azabu, Minato-ku, Tokyo, 106-0044　Google Map
Established October, 2019
Paid-in Capital 1.01516 billion JPY (including capital surplus)
Representative Yuichi Tamura, President and CEO
Officers CDO Mineki Takechi
Our Mission
  • １．Research, development, manufacturing, and sales of automated diagnosis systems using artificial intelligence
  • ２．Research, development, manufacturing, sales, patent licensing and contracted development services for computer software
  • ３．Research, development, import/export, manufacturing, sales, lending, repair, patent licensing and contracted services for pharmaceuticals, medical devices and other general machinery and equipment, etc.
Qualifications Class II Marketing License for Medical Devices (License No. 13B2X10429), Medical Device Manufacturer (Registration No. 13BZ201666)

Contact

    *Required entry

    Types of Inquiry*

    Affiliated Institution

    Full Name *

    Email Address *

    Content of Inquiry *